甲状腺癌的RNA相关标志物

doi:10.3760/cma.j.issn.1673-422X.2017.07.014

摘要/Abstract

摘要： 目前甲状腺癌的前期诊断仍存在无法跨越的领域，近年来诸多学者致力于分子标志物的研究，发现与甲状腺癌相关的RNA标志物主要有微小RNA、端粒酶反转录酶、肠三叶因子及HMGA2基因等。不同基因与不同类型甲状腺癌的发生、发展密切相关，有的甚至会影响甲状腺癌的转移。

关键词: 甲状腺肿瘤, 微RNAs

Abstract: In recent years, there is still an unbridgeable area in the early diagnosis of thyroid carcinoma. Many scholars are committed to the research of molecular markers, and find that RNA markers associated with thyroid carcinoma are microRNAs, human telomerase reverse transcripase, trefail factor 3 and HMGA2 genes. Different genes are closely related to the occurrence, development of different types of thyroid cancers, and some genes may even affect the transfer of thyroid carcinoma.

Key words: Thyroid neoplasms, MicroRNAs

陈丽丽，蓝奎旭. 甲状腺癌的RNA相关标志物[J]. 国际肿瘤学杂志, 2017, 44(7): 534-536.

Chen Lili, Lan Kuixu. RNA related markers of thyroid cancer[J]. Journal of International Oncology, 2017, 44(7): 534-536.

参考文献

［1］ Kim WB. A closer look at papillary thyroid carcinoma［J］. Endocrinol Metab (Seoul), 2015, 30(1): 1-6. DOI: 10.3803/EnM.2015.30.1.1. ［2］ Bisof V, Rakusic Z, Despot M. Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?［J］. Eur Arch Otorhinolaryngol, 2015, 272(7): 1553-1567. DOI: 10.1007/s00405-014-3108-1. ［3］ Sung JY, Na DG, Kim KS, et al. Diagnostic accueacy of fineneedle aspiration versus coreneedle biopsy for the diagnosis of thyroid malignancy in a clinical cohort［J］. Eur Radiol, 2012, 22(7): 15641572. DOI: 10.1007/s0033001224056. ［4］ Renshaw AA. Significance of repeatedly nondiagnostic thyroid fineneedle aspirations［J］. Am J Clin Pathol, 2011, 135(5): 750-752. DOI: 10.1309/AJCP8FX5CLPISSSK. ［5］ Anderson TJ, Atalay MK, Grand DJ, et al. Management of nodules with initially nondiagnostic results of thyroid fineneedle aspiration: can we avoid repeat biopsy?［J］. Radiology, 2014, 272(3): 777-784. DOI: 10.1148/radiol.14132134. ［6］ Yang F, Yi F, Zheng Z, et al. Charactreization of a carcinogenesisassociated long noncoding RNA［J］. RNA Biol, 2012, 9(1): 110-116. DOI: 10.4161/rna.9.1.18332. ［7］ Vriens MR, Weng J, Suh I, et al. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer［J］. Cancer, 2012, 118(13): 3426-3432. DOI: 10.1002/cncr.26587. ［8］ Keutgen XM, Filicori F, Crowley MJ, et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration［J］. Clin Cancer Res, 2012, 18(7): 2032-2038. DOI: 10.1158/1078-0432.CCR-11-2487. ［9］ Huang Y, Liao D, Pan L, et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation［J］. Eur J Endocrinol,2013, 168(5): 675-681. DOI: 10.1530/EJE-12-1029. ［10］ Liu CG, Calin GA, Meloon B, et al. An oligonucleotide microchip for genomewide microRNA profiling in human and mouse tissues［J］. Proc Natl Acad Sci USA, 2014, 101(26): 9740-9744. DOI: 10.1073/pnas.0403293101. ［11］ Dettmer M, Vogetseder A, Durso MB, et al. MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas［J］. J Clin Endocrinol Metab, 2013, 98(1): E1-E7. DOI: 10.1210/jc.2012-2694. ［12］ Yu S, Liu Y, Wang J, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma［J］. J Clin Endocrinol Metab, 2012, 97(6): 2084-2092. DOI: 10.1210/jc.2011-3059. ［13］ Moran VA, Perera RJ, Khalil AM, et al. Emerging functional and mechanistic paradigms of mammalian long noncoding RNAs［J］. Nucleic Acids Res, 2012, 40(14): 6391-6400. DOI: 10.1093/nar/gks296. ［14］ Wang Y, Guo Q, Zhao Y, et al. BRAFactivated long noncoding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma［J］. Oncol Lett, 2014, 8(5): 1947-1952. DOI: 10.3892/ol.2014.2487. ［15］ Rogounovitch TI, Bychkov A, Takahashi M, et al. The common genetic variant rs944289 on chromosome 14q13.3 associates with risk of both malignant and benign thyroid tumors in the Japanese population［J］. Thyroid, 2015, 25(3): 333-340. DOI: 10.1089/thy.2014.0431. ［16］翁侠, 洪晓明. LincRNAPVT1在甲状腺癌组织中的表达及意义［J］.实用肿瘤杂志, 2017, 32(1): 57-61. DOI: 10.13267/j.cnki.syzlzz.2017.01.014. ［17］ Johnsson P, Morris KV. Expanding the functional role of long noncoding RNAs［J］. Cell Res, 2014, 24(11): 1284-1285. DOI: 10.1038/cr.2014.104. ［18］ Sugishita Y, Kammori M, Yamada O, et al. Biological differential diagnosis of follicular thyroid tumor and Hürthle cell tumor on the basis of telomere length and hTERT expression［J］. Ann Surg Oncol, 2014, 21(7): 2318-2325. DOI: 10.1245/s10434-014-3552-6. ［19］ Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a majr indicator of poor outcome in differentiated thyroid carcinomas［J］. J Clin Endocrinol Metab, 2014, 99(5): E754-E765. DOI: 10.1210/jc.2013-3734. ［20］ Patel MR, Stadler ME, Deal AM, et al. STT3A, C1orf24, TFF3: putative markers forcharacterization of follicular thyroid neoplasms from fineneedle aspirates［J］. Laryngoscope, 2011, 121(5): 983-989. DOI: 10.1002/lary.21736. ［21］ Im S, Yoo C, Jung JH, et al. Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: correlation with clinicopathological parameters and prognosis［J］. Int J Med Sci, 2013, 10(2): 133140. DOI: 10.7150/ijms.5500. ［22］ Bernstein HG, Dobrowolny H, Trübner K, et al. Differential regional and cellular distribution of TFF3 peptide in the human brain［J］. Amino Acids, 2015, 47(5): 1053-1063. DOI: 10.1007/s00726-015-1938-9. ［23］王维健, 政峰. TFF3和半乳糖凝集素3在甲状腺肿瘤鉴别诊断中的临床意义［J］. 同济大学学报: 医学版, 2016, 37(6): 115-119. DOI: 10.16118/j.1008-0392.2016.06.023. ［24］ Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012［J］. CA Cancer J Clin, 2012, 62(1): 10-29. DOI: 10.3322/caac.20138. ［25］ Jin L, Lloyd RV, Henry MR, et al. The diagnostic utility of combination of HMGA2 and IMP3 qRTPCR testing in thyroid neoplasms［J］. Appl Immunohistochem Mol Morphol, 2015, 23(1): 36-43. DOI: 10.1097/PAI.0000000000000031.

[1]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[2]	王子琪, 罗盼, 叶永英, 吴伟莉. 甲状腺腺样囊性癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(3): 191-192.
[3]	张劲男, 刘邦卿, 李军, 刘晓辉. BHLHE40靶向HMGA2激活氧化磷酸化通路降低甲状腺癌细胞对顺铂敏感性的研究[J]. 国际肿瘤学杂志, 2023, 50(7): 398-406.
[4]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[5]	周仁邦, 张仲传, 许志远, 朱勋兵. miR-219a-5p通过负调控HMGA2抑制骨肉瘤U2OS细胞增殖、侵袭和迁移[J]. 国际肿瘤学杂志, 2022, 49(4): 193-198.
[6]	金嘉会, 陈存海, 马学真. 放射相关miRNA在乳腺癌放疗中的作用[J]. 国际肿瘤学杂志, 2022, 49(12): 735-738.
[7]	井文君, 赵文文, 冯青青, 赵文飞, 赵丽丽, 张雪, 魏红梅. miR-34家族用于胃癌治疗的分子基础及临床前景[J]. 国际肿瘤学杂志, 2022, 49(11): 681-686.
[8]	李劲浩, 王桂东, 李雪菲, 刘子琳, 孟凯龙. 静脉期CT值预测甲状腺乳头状癌中央组淋巴结转移的临床研究[J]. 国际肿瘤学杂志, 2022, 49(10): 581-585.
[9]	罗丽云, 赖灿辉, 梁仁佩, 杨爱武, 林志敏. 晚期胃癌中miR-524-5p与SOX9表达的相关性及其对化疗疗效和预后的影响[J]. 国际肿瘤学杂志, 2022, 49(1): 45-50.
[10]	吴宇平, 张潇宇, 陆克义. PD-L1在甲状腺癌中的作用机制及其在诊疗中的应用[J]. 国际肿瘤学杂志, 2021, 48(9): 560-563.
[11]	冯志平, 杨传周, 陈婷, 朱家伦, 刘超, 吕娟, 陆建梅, 邓智勇. BRD4抑制剂通过BRD4/miR-106b-5p/P21分子轴特异性抑制野生型Kras分化型甲状腺癌发展[J]. 国际肿瘤学杂志, 2021, 48(8): 463-472.
[12]	刘佩, 蒲嘉泽, 黄雯, 汪斐. 吉非替尼敏感与耐药NSCLC患者miR-200c、miR-19a、miR-155表达差异及其对患者预后的影响[J]. 国际肿瘤学杂志, 2021, 48(7): 409-414.
[13]	王阳, 刘芊, 龙辉, 吴清明. 结直肠癌标志物粪便检测的研究现状[J]. 国际肿瘤学杂志, 2021, 48(7): 441-444.
[14]	程一鸣, 李刚, 王振明, 吕倩文, 李世荣. 血清miR-196a-5p、miR-105-5p在良恶性肺结节鉴别诊断中的价值[J]. 国际肿瘤学杂志, 2021, 48(5): 282-286.
[15]	邓波儿, 孔为民. 子宫内膜癌的表观遗传学研究进展[J]. 国际肿瘤学杂志, 2021, 48(3): 184-188.